Table 1

Patient characteristics and angiographic data

Total
N=518
Incomplete revascularisation*
n=287
Complete revascularisation*
n=231
p Value
Gender (male)76%74%78%0.24
Age (years)63±1264±1362±12 0.02
Obesity (BMI≥30 kg/m2)16%17%15%0.41
Diabetes12%14%10%0.15
Hypercholesterolaemia†17%19%15%0.30
Hypertension‡37%40%34%0.17
Current smoker44%43%45%0.58
Family history of CAD38%38%38%0.90
Presenting in Killip class≥27%10%4% 0.006
Culprit vessel
Left main1%1%2%0.50
 RCA42%39%45%0.20
 LAD41%46%35% 0.02
 LCx16%14%18%0.19
Three-vessel CAD33%42%22% <0.001
eGFR ≤60 mL/min/1.73 m²13%15%9% 0.04
Troponin T level4.57
(IQR 1.77–8.93)
4.91
(IQR 1.86–9.22)
4.40
(IQR 1.58–8.60)
0.28
Peak cardiac troponin T level ≥3.5 µg/L59%61%56%0.18
LV ejection fraction47±1046±1047±100.07
LV ejection fraction ≤40%28%31%25%0.13
Blood pressure at discharge
 Systolic116±17115±16118±180.10
 Diastolic70±1169±1071±120.12
Medication at discharge
 Beta-blocker93%92%94%0.36
 Aspirin96%96%97%0.75
 Clopidogrel99%99%99%0.80
 ACE inhibitor/ARB96%96%97%0.55
 Statin98%98%98%0.71
  • *Complete revascularisation was defined as treating all present significant coronary artery stenosis ≥70% during primary PCI or before discharge.

  • †Serum total cholesterol ≥230 mg/dL and/or serum triglycerides ≥200 mg/dL or treatment with lipid-lowering drugs.

  • ‡Defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or the use of antihypertensive medication.

  • ARB, angiotensin receptor blockers; BMI, body mass index; CAD, coronary artery disease; eGFR, glomerular filtration rate estimated using the Cockroft-Gault formula; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LV, left ventricle; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction.

  • A two-sided p value of <0.05 was considered statistically significant.